Skip to content

Yoshihiro Noda

Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.

2 papers in the library · 3 citations · publishing 2025

Papers

Glutamate plus glutamine to GABA ratio as a predictor of ketamine response in treatment-resistant depression: A double-blind, randomized, open-label extension study.

Journal of affective disorders August 15, 2025 Yohei Ohtani, Hideaki Tani, Shiori Honda et al. 3 citations

About 30% of people with treatment-resistant depression respond to ketamine, but reliable predictors of response have been lacking. This study examined whether the ratio of glutamate+glutamine (Glx) to GABA in the dorsal anterior cingulate cortex (dACC) could predict ketamine's effectiveness. In a double-blind randomized trial with an open-label extension involving 30 participants, a higher baseline Glx/GABA ratio in the dACC correlated with greater improvement in depression scores (measured by the HDRS-17). After ketamine treatment, a reduction in this ratio also correlated with symptom improvement. The findings suggest that an excitatory-inhibitory imbalance in the dACC may help predict which patients will benefit from ketamine therapy.

247. DOES EXCITATORY/INHIBITORY BALANCE PREDICT KETAMINE RESPONSE IN TREATMENT-RESISTANT DEPRESSION? A DOUBLE-BLIND RANDOMIZED CONTROLLED TRIAL WITH 1H-MRS

The International Journal of Neuropsychopharmacology August 1, 2025 Yuko Ohtani, Hiroe Tani, Shiori Honda et al.

A higher baseline ratio of glutamate+glutamine (Glx) to GABA in the dorsal anterior cingulate cortex predicted greater improvement in depressive symptoms after ketamine treatment in adults with treatment-resistant depression. In the ketamine group, a reduction in this Glx/GABA ratio correlated with symptom improvement, but no such association appeared in the placebo group. The findings suggest that the balance between excitatory and inhibitory neurotransmission in this brain region may serve as a biomarker for predicting antidepressant response to ketamine.